{"id":1067,"date":"2002-03-19T14:45:51","date_gmt":"2002-03-19T13:45:51","guid":{"rendered":"https:\/\/www.francecoag.org\/?post_type=publications_science&p=1067"},"modified":"2025-03-19T14:52:54","modified_gmt":"2025-03-19T13:52:54","slug":"gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra","status":"publish","type":"publications_science","link":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/","title":{"rendered":"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort"},"content":{"rendered":"

https:\/\/pubmed.ncbi.nlm.nih.gov\/11841442\/<\/a><\/p>\n

\n
\n
    \n
  • PMID: <\/span> 11841442<\/strong> <\/span><\/li>\n<\/ul>\n<\/div>\n<\/header>\n
    \n

    Abstract<\/h2>\n
    \n

    Human parvovirus B19 (B19) has been transmitted by some brands of virally attenuated plasma-derived factor VIII (FVIII) or IX (FIX) concentrates. To quantify the differences of human parvovirus B19 risk transmission between albumin-stabilized recombinant factor and plasma-derived factor, we studied the prevalence of IgG antibodies to B19 (anti-B19) in 193 haemophiliac children between 1 and 6-years of age who had previously been treated with albumin-stabilized recombinant FVIII only (n = 104), and in children previously treated with solvent\/detergent high-purity non-immunopurified and non-nanofiltered FVIII or IX concentrates (n = 89). Association between the prevalence of anti-B19 and the treatment group was analysed using multivariate logistic regression. Age, severity and type of haemophilia, number of cumulative days of exposure to factor VIII or IX, previous history of red blood cells or plasma transfusion were considered as potential confounding variables. A higher prevalence of anti-B19 was found in children previously treated with solvent\/detergent high-purity non-immunopurified and non-nanofiltered FVIII or IX concentrates than in children treated with albumin- stabilized recombinant FVIII only (OR: 22.3; CI: 7.9-62.8), independently of the other factors studied.<\/p>\n<\/div>\n<\/div>\n","protected":false},"parent":0,"template":"","keyword":[],"class_list":["post-1067","publications_science","type-publications_science","status-publish","hentry"],"acf":[],"yoast_head":"\nGaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort - FranceCoag<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort - FranceCoag\" \/>\n<meta property=\"og:description\" content=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11841442\/ PMID: 11841442 Abstract Human parvovirus B19 (B19) has been transmitted by some brands of virally attenuated plasma-derived factor VIII […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/\" \/>\n<meta property=\"og:site_name\" content=\"FranceCoag\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-19T13:52:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\\\/\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\\\/\",\"name\":\"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort - FranceCoag\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#website\"},\"datePublished\":\"2002-03-19T13:45:51+00:00\",\"dateModified\":\"2025-03-19T13:52:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications scientifiques\",\"item\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/publications_science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/\",\"name\":\"FranceCoag\",\"description\":\"La cohorte FranceCoag accompagne plus de 10.000 patients atteints d\u2019une maladie h\u00e9morragique\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#organization\",\"name\":\"FranceCoag\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.francecoag.org\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/logo-france-COAG-1.png\",\"contentUrl\":\"https:\\\/\\\/www.francecoag.org\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/logo-france-COAG-1.png\",\"width\":600,\"height\":260,\"caption\":\"FranceCoag\"},\"image\":{\"@id\":\"https:\\\/\\\/www.francecoag.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort - FranceCoag","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/","og_locale":"en_US","og_type":"article","og_title":"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort - FranceCoag","og_description":"https:\/\/pubmed.ncbi.nlm.nih.gov\/11841442\/ PMID: 11841442 Abstract Human parvovirus B19 (B19) has been transmitted by some brands of virally attenuated plasma-derived factor VIII […]","og_url":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/","og_site_name":"FranceCoag","article_modified_time":"2025-03-19T13:52:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/","url":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/","name":"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort - FranceCoag","isPartOf":{"@id":"https:\/\/www.francecoag.org\/en\/#website"},"datePublished":"2002-03-19T13:45:51+00:00","dateModified":"2025-03-19T13:52:54+00:00","breadcrumb":{"@id":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.francecoag.org\/en\/publications_science\/gaboulaud-v-et-al-prevalence-of-igg-antibodies-to-human-parvovirus-b19-in-haemophilia-children-treated-with-recombinant-factor-fviii-only-or-with-at-least-one-plasma-derived-fviii-or-fix-concentra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.francecoag.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications scientifiques","item":"https:\/\/www.francecoag.org\/en\/publications_science\/"},{"@type":"ListItem","position":3,"name":"Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort"}]},{"@type":"WebSite","@id":"https:\/\/www.francecoag.org\/en\/#website","url":"https:\/\/www.francecoag.org\/en\/","name":"FranceCoag","description":"La cohorte FranceCoag accompagne plus de 10.000 patients atteints d\u2019une maladie h\u00e9morragique","publisher":{"@id":"https:\/\/www.francecoag.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.francecoag.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.francecoag.org\/en\/#organization","name":"FranceCoag","url":"https:\/\/www.francecoag.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.francecoag.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.francecoag.org\/wp-content\/uploads\/2023\/12\/logo-france-COAG-1.png","contentUrl":"https:\/\/www.francecoag.org\/wp-content\/uploads\/2023\/12\/logo-france-COAG-1.png","width":600,"height":260,"caption":"FranceCoag"},"image":{"@id":"https:\/\/www.francecoag.org\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science\/1067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science"}],"about":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/types\/publications_science"}],"version-history":[{"count":1,"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science\/1067\/revisions"}],"predecessor-version":[{"id":1068,"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/publications_science\/1067\/revisions\/1068"}],"wp:attachment":[{"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/media?parent=1067"}],"wp:term":[{"taxonomy":"keyword","embeddable":true,"href":"https:\/\/www.francecoag.org\/en\/wp-json\/wp\/v2\/keyword?post=1067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}